Medigene AG, a biotechnology company, develops immunotherapy platforms to treat a range of cancers in various stages. It operates through two segments, Immunotherapies and Other Products. The company develops Dendritic cell vaccines in phase I/II clinical trials; and T-cell receptor-modified T cells and T-cell-specific monoclonal antibodies in preclinical development phase. It also develops Veregen for the treatment of genital warts; EndoTAG-1 for the treatment of solid tumors; and RhuDex for the treatment of autoimmune diseases. Medigene AG has strategic partnership with bluebird bio, Inc. for the development of T cell receptors; and research collaboration agreements with RXi Pharmaceuticals Corporation and Structured Immunity. The company was founded in 1994 and is headquartered in Martinsried, Germany.
Industry, Sector and Symbol
Stock Exchange ETR
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolETR:MDG1
CUSIPN/A
Phone+49-89-2000330
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-142.41%
Return on Equity-14.40%
Return on Assets-11.01%
Miscellaneous
EmployeesN/A
Outstanding Shares22,120,000
Market Cap$392.27 million
MediGene (ETR:MDG1) Frequently Asked Questions
What is MediGene's stock symbol?
MediGene trades on the ETR under the ticker symbol "MDG1."
What price target have analysts set for MDG1?
3 analysts have issued 12-month price targets for MediGene's stock. Their predictions range from €14.00 to €22.00. On average, they anticipate MediGene's share price to reach €17.17 in the next twelve months. This suggests a possible upside of 32.4% from the stock's current price. View Analyst Price Targets for MediGene.
What is the consensus analysts' recommendation for MediGene?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediGene in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for MediGene.
Who are some of MediGene's key competitors?
Some companies that are related to MediGene include Sirtex Medical (SRX), Genus (GNS), Biotest (BIO), ProMetic Life Sciences (PLI), Genfit (GNFTF), Mesoblast (MSB), Theratechnologies (TH), Mesoblast (MEOBF), Emerald Health Therapeutics (EMH), Starpharma (SPL), Oxford BioMedica (OXB), BioTime (BTX), Resverlogix (RVX), 22nd Century Group (XXII) and Protalix Biotherapeutics (PLX).
Who are MediGene's key executives?
MediGene's management team includes the folowing people:
- Prof. Horst Domdey, Co-Founder & Chairman of the Supervisory Board (Age 67)
- Prof. Dolores J. Schendel, CEO, Chief Scientific Officer & Member of Exec. Management Board
- Prof. Ernst-Ludwig Winnacker, Co-Founder & Chairman Scientific Advisory Board (Age 77)
- Dr. Thomas Taapken, CFO & Member of Exec. Management Board
- Dr. Kai Pinkernell, Chief Medical Officer, Chief Devel. Officer & Member of Exec. Management Board
Has MediGene been receiving favorable news coverage?
Press coverage about MDG1 stock has been trending somewhat positive this week, according to Accern. The research firm rates the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. MediGene earned a news impact score of 0.18 on Accern's scale. They also assigned media stories about the company an impact score of 46.57 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future. View Recent Headlines for MediGene.
What is MediGene's stock price today?
One share of MDG1 stock can currently be purchased for approximately €12.97.
How big of a company is MediGene?
MediGene has a market capitalization of $392.27 million.
How can I contact MediGene?
MediGene's mailing address is Lochhamer Strasse 11, PLANEGG, 82152, Germany. The company can be reached via phone at +49-89-2000330.
MarketBeat Community Rating for MediGene (ETR MDG1)
MarketBeat's community ratings are surveys of what our community members think about MediGene and other stocks. Vote "Outperform" if you believe MDG1 will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MDG1 will underperform the S&P 500 over the long term. You may vote once every thirty days.
